Borderless Biotech - Mexico's Emerging Life ... - San Diego Dialogue
Borderless Biotech - Mexico's Emerging Life ... - San Diego Dialogue
Borderless Biotech - Mexico's Emerging Life ... - San Diego Dialogue
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
a briefing paper by <strong>San</strong> <strong>Diego</strong> <strong>Dialogue</strong><br />
a division of UCSD Extension<br />
with generous funding by Merck & Co. Inc.<br />
developed under contract by Crossborder Group Inc.<br />
June 2007<br />
<strong>Borderless</strong> <strong>Biotech</strong><br />
& Mexico’s <strong>Emerging</strong><br />
<strong>Life</strong> Sciences Industry<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- []
Executive Summary<br />
The <strong>San</strong> <strong>Diego</strong> <strong>Dialogue</strong>, a program of University Extension at<br />
the University of California, <strong>San</strong> <strong>Diego</strong>, has spent the last three<br />
years focusing on issues of innovation and competitiveness in<br />
the crossborder region. On the heels of the 2006 publication of<br />
a major research report on the <strong>San</strong> <strong>Diego</strong>/Baja California Region,<br />
<strong>Borderless</strong> Innovation, a relationship was established<br />
with the global pharmaceutical company, Merck and its subsidiary,<br />
Merck Sharpe & Dohme in Mexico City. Merck has had a<br />
longstanding commitment to innovation in the United States<br />
and, in recent years, its attention has turned to innovation in<br />
Mexico and Latin America. With support from Merck, the <strong>San</strong><br />
<strong>Diego</strong> <strong>Dialogue</strong> launched a <strong>Life</strong> Sciences Gateway Initiative, with<br />
four strategic life science regions identified by Merck in Mexico<br />
– Guanajuato, Jalisco, Morelos and Nuevo León. The focus of<br />
the partnership has been to build long term relationships between<br />
the R&D, technology commercialization and life science<br />
business communities in Mexico with their counterparts in California and across the United States.<br />
This briefing paper is an initial look at the multiplicity of opportunities that exist in Mexico. It provides<br />
some insight into what may be the barriers to harnessing necessary capabilities on the part of the<br />
Mexicans, but also vis-à-vis perceptions of Mexico by the life science clusters in <strong>San</strong> <strong>Diego</strong> and Orange<br />
Counties. The report highlights the contributions Mexican scientists and companies have made to the<br />
development of life sciences, and provides introductions to the regions identified by Merck. It is also<br />
a reminder of the capabilities of Baja California, and their connection to the greater <strong>San</strong> <strong>Diego</strong> region.<br />
What is significant to the U.S. is the extent to which Mexican regions are mobilizing national, state and<br />
local resources to coordinate their research with economic and workforce development. This document<br />
points out that there has been notable growth in research activity across Mexico measured by<br />
increasing numbers of research centers and science graduates, growth in patent activity, expansion of<br />
incubators and infrastructure of innovation, and growth in advanced manufacturing and clinical trial<br />
activities across Mexico.<br />
These growing assets, and commitments from Mexico, represent a promising development for <strong>San</strong> <strong>Diego</strong><br />
and California. <strong>San</strong> <strong>Diego</strong> is one of the most vibrant life science research and development communities<br />
in the world. The level of research funding, combined with the amount of venture capital coming<br />
into <strong>San</strong> <strong>Diego</strong> companies, means that <strong>San</strong> <strong>Diego</strong> has become a global hub in the life sciences arena.<br />
The <strong>San</strong> <strong>Diego</strong> innovation community is linked to research, commercialization, investment and marketing<br />
around the globe, and as such, is an appropriate gateway for a life sciences initiative across Mexico.<br />
This briefing paper is based on personal visits to the Mexican regions described in the report, as well<br />
as a strategy for building relationships between the many partners in any effective innovation system.<br />
Seminars and roundtables over the next 12 months involving peer-to-peer interactions of leadership<br />
from Mexico with leadership in California will focus on IP strategies, venture investing, strategic<br />
partnering in manufacturing and clinical research, as well as basic research partnerships in areas of<br />
biomedicine and biotechnology. The data reported in this report will be amplified in subsequent white<br />
papers, which will go into much greater depth about each of the regions. For the purposes of this June<br />
Forum Fronterizo, this briefing paper has been developed as a way of informing and inspiring potential<br />
partners, particularly in <strong>San</strong> <strong>Diego</strong> and across California, to investigate the opportunities to grow a<br />
borderless life sciences community by engaging our friends and potential partners in Mexico.<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [1]
A Vision of <strong>Borderless</strong> <strong>Biotech</strong><br />
What do Genentech, the birth control pill, biomedical devices, and biotechnology have to do with<br />
Mexico? More than most people think – and that creates a unique opportunity for not just the United<br />
States, but also for the California life sciences industry in particular. While much attention is focused<br />
on Europe and Asia, several regions within Mexico are emerging as highly capable life sciences research<br />
centers, as well as sites for current – and future – industry growth.<br />
These regions, and the potential opportunity they present for collaboration with the <strong>San</strong> <strong>Diego</strong> and<br />
California life sciences industry, are the focus of this first briefing paper – and the focus of a 18-month<br />
binational project launched last December, 2006, between UCSD Extension’s <strong>San</strong> <strong>Diego</strong> <strong>Dialogue</strong> and<br />
Merck Sharp & Dohme (Merck) - the <strong>Life</strong> Sciences Gateway Initiative. Working with government and<br />
life sciences leaders in some of Mexico’s most innovative regions (including the states of Guanajuato,<br />
Jalisco, Morelos, and Nuevo León), UCSD and Merck aim to “build sustainable binational relationships<br />
among researchers, scientists and investors for the purposes of stimulating and nurturing the lifecycle<br />
of innovation….” 1<br />
This collaborative effort joins together two separate ongoing efforts – Merck’s multi-year initiative to<br />
promote life sciences in Mexico through research, events, and education; and <strong>San</strong> <strong>Diego</strong> <strong>Dialogue</strong>’s<br />
2006 binational study, <strong>Borderless</strong> Innovation – a groundbreaking report that analyzed opportunities in<br />
the <strong>San</strong> <strong>Diego</strong>-Baja California region to increase the competitiveness of science and technology<br />
industries. Combined with the efforts and activities within each region, the result is – so to speak – a<br />
triple helix of life sciences leadership.<br />
While not a focus of the current project, previous research done for the <strong>Borderless</strong> Innovation report<br />
clearly demonstrated that Baja California is also one of Mexico’s emerging life sciences regions. In<br />
fact, each of the five states that will be discussed – Guanajuato, Jalisco, Morelos, Nuevo León and Baja<br />
California – have their own strengths and specialties. Most also share some of the same challenges that<br />
can potentially be best solved through unified efforts, as well as shared opportunities.<br />
Genentech and Mexican Innovators<br />
In California in the late-1970s, Genentech was not as well known as it is today. One of its<br />
co-founders, Dr. Herbert Boyer, was a professor of biochemistry and biophysics at UCSF,<br />
where several members of his research team, including Mexican-born Francisco Bolivar and<br />
Californian Ray Rodriguez, were diligently working to create a safe and effective biological<br />
mechanism to facilitate cloning of special bacteria. Their answer: a “plasmid vector” – a<br />
small, self-replicating genetic element with built-in coding of enzymes that allow its host –<br />
a bacteria, for instance – to thrive in environments in which many other bacteria cannot (for<br />
instance, in the presence of antibiotics).<br />
The resulting genetic package was the plasmid pBR322 (the “B” for “Bolivar”, the “R” for<br />
Rodriguez) – designed to be resistant to two antibiotics (ampicillin and tetracycline). When<br />
placed into a fast-growing bacterial host like E. coli, pBR322 allows the altered bacteria to<br />
be selected (screening negative bacteria). By subsequently modifying this plasmid to<br />
“carry” human genetic materials, they were able to stimulate the production of certain<br />
hormones by the bacterial host – such as insulin. Once a modified plasmid vector like<br />
pBR322 is coupled with a gene to promote insulin production and then inserted into an E.<br />
coli bacteria, the result is a self-replicating, genetically-modified cellular factory that can<br />
safely synthesize human insulin – a process that helped to launch Genentech as a multibillion<br />
dollar company.<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [2]
Trends in Mexico’s <strong>Life</strong> Sciences Clusters<br />
biotechnology<br />
"san diego"<br />
biotechnology<br />
india<br />
biotechnology<br />
mexico<br />
biotechnology<br />
monterrey<br />
biotechnology<br />
guadalajara<br />
biotechnology<br />
cuernavaca<br />
biotechnology<br />
irapuato<br />
"Google TM Metric" of<br />
Selected Search Terms<br />
2,010,000<br />
1,300,000<br />
133,000<br />
74,200<br />
48,000<br />
15,400<br />
Trade Trends<br />
3,010,000<br />
Measurement of the<br />
total number of<br />
returned results<br />
using the Google TM<br />
search engine<br />
According to the latest data from the US Department of<br />
Commerce, trade between the US and Mexico in biotechnology<br />
and life sciences goods is on the increase. In 2006,<br />
trade in these goods had reached nearly $3 billion in total<br />
trade, and had an average annual growth of 15% between<br />
2003 and 2006.<br />
What are these goods? The US Census Bureau defines these<br />
Advanced Technology Products as:<br />
In most discussions about the global life sciences industry, Mexico<br />
is not usually considered a prime location for innovations and high<br />
technology. This lack of general awareness, in fact, can be<br />
demonstrated with a simple metric comparing the number of<br />
“hits” certain phrases receive on the internet using the search<br />
engine Google.<br />
As seen at left, when combining the word “biotechnology” with<br />
various phrases, such as “<strong>San</strong> <strong>Diego</strong>”, “Mexico”, “Guadalajara”,<br />
etc., relatively few English-language pages apparently exist that<br />
reference some of Mexico’s biotech regions. While admittedly life<br />
sciences-related activities are still an emerging part of the economy,<br />
and this Google metric is far from a perfect measurement of<br />
the actual situation, it does provide at least an indication of the<br />
perceived degree of biotechnology activity (and perhaps perceived<br />
capability) in Mexico. That said, other indicators show more<br />
positive signs.<br />
<strong>Biotech</strong>nology Products<br />
Focuses on medical and industrial applications of advanced<br />
scientific discoveries in genetics to<br />
the creation of new drugs, hormones and<br />
other therapeutic items for both agricultural<br />
and human use.<br />
What are <strong>Life</strong> Sciences?<br />
<strong>Life</strong> Sciences Products<br />
Concentrates on the application of scientific<br />
advances (other than biological) to<br />
medical science. Recent advances, such as<br />
nuclear resonance imaging, echocardiography,<br />
and novel chemistry, coupled with<br />
new production techniques for the manufacture<br />
of drugs have led to many new<br />
products for the control or eradication of<br />
disease.<br />
To use the definition outlined in the highly-acclaimed<br />
2005 study by the Council on Competitiveness and<br />
Global Bioeconomy Consulting, “Catalyzing Cross-Border<br />
Innovation: The Mexican <strong>Life</strong> Sciences Initiative”,<br />
life sciences are:<br />
“...broadly defined to include all biological technologies<br />
and applications. This includes: biotechnology,<br />
pharmaceuticals, plant and animal technologies, medical<br />
devices, healthcare (e.g. translational research,<br />
clinical trials), biological related information technology<br />
(e.g. bioinformatics, telemedicine), as well as<br />
biological-related production and manufacturing.”<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [3]<br />
US$ billions<br />
US - Mexico Trade in<br />
<strong>Biotech</strong>nology & <strong>Life</strong> Science Goods<br />
(2003-2006, US$billions)<br />
3.0<br />
2.5<br />
2.0<br />
1.5<br />
1.0<br />
0.5<br />
0.0<br />
2003 2004 2005 2006<br />
US Exports Imports
Birth Control and the “Dupont of Mexico”<br />
Mexico’s innovations in life sciences have not been limited to the last two decades. In fact, one<br />
of the pharmaceutical industry’s early success stories – the birth control pill – has roots in<br />
Mexico…literally. Early steroid research in the 1930’s showed that progesterone could inhibit<br />
ovulation in women, but commercial applications weren’t feasible since steroids at that time<br />
were isolated in very small amounts from animal glands – an expensive process. Dr. Russell Marker<br />
(a Chemistry professor from the University of Pennsylvania) developed an alternative process that<br />
converted toxic steroids (sapogenins) into the pregnancy hormone progesterone. Dr. Marker also<br />
discovered a viable source for this: the cabeza de negro – a wild yam in Mexico.<br />
In 1944, Dr. Marker and two entrepreneurs in Mexico City founded Laboratorios Syntex to develop<br />
and commercialize crystalline progesterone. While Dr. Marker left after one year following a<br />
dispute, Syntex’s co-founders soon hired Dr. George Rosenkranz, who envisioned building Syntex<br />
into “the Dupont of Mexico.” Dr. Rosenkranz’s team of researchers – including Dr. Alejandro<br />
Zaffaroni – not only were able to ultimately develop commercial quantities of progesterone, but<br />
ultimately won an international race in 1951 to synthetically develop cortisone (beating out a<br />
rival team from Merck, among others). Syntex’s researchers also included Luis Miramontes, a<br />
college student from UNAM in Mexico, who was instrumental in synthesizing norethindrone – the<br />
active ingredient to one of the two earliest oral birth control formulas.<br />
In 1964, Syntex expanded to Palo Alto, California, where the talents of Drs. Rosenkranz,<br />
Zaffaroni, and other Syntex alumni (including Dr. Carl Djerassi), helped contribute to the growth<br />
of California’s life sciences industry…<br />
Trends in <strong>Life</strong> Sciences Education & Workforce<br />
Raw trade figures tell one story. Another story can be revealed by the notable annual increases in<br />
doctoral graduates specializing in key areas of science – including Agricultural Sciences, Natural &<br />
Exact Sciences, Health Sciences, and Engineering & Technology. While the number of those receiving<br />
doctorates in these areas still is relatively small<br />
– an estimated 1,147 in all of 2005 – the numbers<br />
are nearly a five-fold increase over the last<br />
decade (with a 17% average annual increase).<br />
It’s also useful to consider that these numbers<br />
do not count the significant numbers of Mexican<br />
scientists that are graduating from doctoral programs<br />
in the United States, Europe, and other<br />
countries.<br />
Annual Doctoral Graduates in Mexico<br />
By Area of Science (1987-2005, CONACYT)<br />
Master’s degree programs are also showing in- 50<br />
creases that bode well for Mexico’s biotech<br />
potential. According to CONACYT (Mexico’s<br />
National Science and Technology Council), the<br />
0<br />
number of new students entering master’s de-<br />
Agricultural Sciences Natural & Exact Sciences<br />
gree programs in life sciences-related fields has<br />
more than doubled since 1995, from 674 stu-<br />
Health Sciences Engineering & Technology<br />
dents entering such programs to more than 1,500 in 2006. It should be noted, however, that these<br />
positive increases have also raised some concerns about the possible lack of high-skilled employment<br />
opportunities in Mexico to absorb these graduates - a critique that underscores the opportunity for<br />
expanding companies to investigate this potentially underutilized workforce.<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [4]<br />
500<br />
450<br />
400<br />
350<br />
300<br />
250<br />
200<br />
150<br />
100<br />
1987<br />
1989<br />
1991<br />
1993<br />
1995<br />
1997<br />
1999<br />
2001<br />
2003<br />
2005
The SNI & <strong>Life</strong> Sciences Publications<br />
In addition to positive educational trends in life<br />
sciences, Mexico’s National Researcher System<br />
also shows some interesting trends. The SNI (to<br />
use its Spanish acronym) is a voluntary but<br />
screened registry of accomplished researchers in<br />
Mexico. As seen at right, between 1995 and<br />
2005, the number of researchers registered in<br />
health, biotechnology, and agricultural sciencerelated<br />
activities nearly doubled.<br />
Over the last decade, the number of scientific<br />
publications that Mexico is generating in life<br />
sciences-related fields has also more than doubled<br />
in some notable areas, including chemistry,<br />
pharmacology, immunology, microbiology, and<br />
plant and animal sciences. These last two areas,<br />
in fact, appear to have relatively high global<br />
strengths – according to Thomson Scientific’s<br />
Essential Science Indicators, Mexico’s microbiological<br />
publications are cited 39% higher than the<br />
world average, and plant & animal science publications<br />
are cited 42% higher than average. While<br />
this relative rating of citations isn’t necessarily as<br />
strong in other areas, it does provide an independent<br />
and global indicator of Mexico’s increasing<br />
scientific capability.<br />
An Update on Medical Devices and FDA<br />
Registered Facilities<br />
<strong>San</strong> <strong>Diego</strong> <strong>Dialogue</strong>’s 2006 publication, <strong>Borderless</strong><br />
Innovation, described biomedical devices – one<br />
component of the life sciences industry – as a<br />
“ready opportunity for regional economic development<br />
efforts”, particularly in light of <strong>San</strong><br />
<strong>Diego</strong>-Baja California’s “largely untapped opportunity<br />
to become one of the major hubs of<br />
biomedical device design, manufacturing, and<br />
global marketing in the world.” While that still<br />
holds true from a regional perspective, such a<br />
vision might also hold true for a California-Mexico<br />
strategic relationship as well, particularly given<br />
the high concentration of biomedical device companies<br />
in Southern California.<br />
Looking at the global expansion of medical device<br />
manufacturing, it’s also an opportunity that both<br />
countries are at risk of losing: between 2003 and<br />
2007, the number of China-based medical device<br />
manufacturers registered with the FDA increased<br />
2,000<br />
1,750<br />
1,500<br />
1,250<br />
1,000<br />
SNI Registered Researchers<br />
By Area of Science<br />
(1995-2005p, CONACYT)<br />
by 156% to over 2,600 companies. During this<br />
same time, China also surpassed Taiwan as having<br />
the largest number of foreign firms registered,<br />
Korea (with a 93% increase in number of firms)<br />
leaped over Canada and the UK, and the number<br />
of registered firms from Mexico fell behind the<br />
number of firms from India and Israel (the number<br />
of FDA registered firms in these latter two countries<br />
growing by 73% and 47% respectively, while Mexico’s<br />
numbers increased by only 12%).<br />
While FDA registered firms are not necessarily a<br />
perfect indicator (it doesn’t, for instance, necessarily<br />
reflect employment or actual amounts of<br />
goods traded), it does underscore the fast-moving<br />
shifts that can occur in an increasingly skilled<br />
global workforce. One state within Mexico that is<br />
taking advantage of this opportunity is actually<br />
right next door: Baja California.<br />
In 2003, Baja California biomedical device firms<br />
employed just over 23,700 individuals. Based on<br />
2006 data from<br />
Producen (an industry<br />
promotion<br />
Baja California<br />
Biomedical Device Employment<br />
research center<br />
34,088<br />
sponsored in part 35,000<br />
by the Government 30,000 26,419<br />
of Baja California), 25,000<br />
estimated employment<br />
in this sector<br />
had risen by 29% to<br />
20,000<br />
15,000<br />
nearly 35,000.<br />
10,000<br />
Such growth is not 5,000<br />
just the result of<br />
0<br />
State and local<br />
2003 2006<br />
economic develop-<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [5]<br />
750<br />
500<br />
250<br />
0<br />
1995<br />
1996<br />
1997<br />
1998<br />
1999<br />
Biology & Chemistry<br />
Medicine & Health Sciences<br />
<strong>Biotech</strong>nology & Agricultural Sciences<br />
2000<br />
2001<br />
2002<br />
2003<br />
2004<br />
2005p/
ment teams, but also by the industry itself, with<br />
the formation of the Cluster de Productos Médicos<br />
de Las Californias – the Medical Products<br />
Cluster of the Californias. This group, made up<br />
of many of Baja California’s largest medical products<br />
manufacturers, is actively encouraging<br />
suppliers to expand into Mexico – something that,<br />
if done correctly, can actually result in more<br />
competitive companies and more employment on<br />
both sides of the US-Mexico border. The secondlargest<br />
market for US medical equipment in Latin<br />
America (after Brazil) could also become one of<br />
the industry’s largest strategic partners, as well.<br />
Pharmaceutical & Clinical Research<br />
As also reported in <strong>Borderless</strong> Innovation, Mexico<br />
is one of the largest pharmaceutical markets in<br />
the world and the largest in Latin America. With<br />
industry sales expected to reach nearly $14 billion<br />
in 2007, nearly all major multinational<br />
pharmaceutical companies are present, including<br />
Merck (operating as Merck, Sharp & Dhome de<br />
México), Abbot Laboratories, Astra Zeneca, Bayer,<br />
Bristol Myers, Eli Lilly, Glaxo Smith Kline,<br />
Roche Syntex, Novartis, Novo Nordisk, Pfizer,<br />
Schering Plough, and Wyeth. While most of these<br />
pharmaceutical giants are involved with manufacturing<br />
activities, many also have made<br />
significant investments in clinical research, as<br />
well.<br />
There are, in addition, several hundred other<br />
pharmaceutical manufacturing companies primarily<br />
involved with generics. Nearly all<br />
pharmaceutical companies are active in the national<br />
industry assocation, CANIFARMA (Cámara<br />
Nacional de la Industria Farmacéutica), which<br />
represents the interests of two major categories<br />
of firms: research-based pharmaceutical firms<br />
(which are represented by a sub-group within<br />
CANIFARMA, called the Asociación Mexicana de<br />
Industrias de Investigación Farmacéutica<br />
[AMIIF]), and generics manufacturers (which are<br />
part of CANIFARMA’s Asociación Nacional de Fabricantes<br />
de Medicamentos – ANAFAM).<br />
As mentioned, most of these firms are involved<br />
with manufacturing (concentrated in Central<br />
Mexico and the Distrito Federal [DF]), with very<br />
little activity in R&D. While at first glance, a<br />
manufacturing focus might be considered a weak-<br />
ness, it also underscores the highly developed<br />
manufacturing expertise within Mexico, where<br />
production is done under high-quality, GMP standards,<br />
often in FDA-registered facilities. For<br />
companies seeking options for lower-cost, highquality,<br />
nearshore manufacturing of pharmaceuticals,<br />
Mexico can play a strategic role in<br />
outsourced manufacturing.<br />
Two examples highlight this evolving opportunity:<br />
<strong>San</strong> <strong>Diego</strong>-based Diversa (covered previously in<br />
<strong>Borderless</strong> Innovation), continues to manufacture<br />
enzymes and proteins through a strategic venture<br />
with FERMIC – one of Latin America’s largest<br />
pharmaceutical fermentation plants located near<br />
Mexico City. FERMIC’s FDA-GMP approved facility<br />
has a production capacity of over 1.3 million<br />
liters, and an expansion underway that will increase<br />
that capacity to 1.9 million liters; in<br />
addition to having an on-site R&D department to<br />
support their own efforts to become more involved<br />
with custom manufacturing of new<br />
biological and biotech products.<br />
The second example demonstrates another type<br />
of evolution: Boehringer Ingelheim – a global<br />
pharmaceutical leader – announced in April 2007<br />
that one of their two Mexico facilities will now<br />
offer contract manufacturing and packaging services<br />
for solid, semi-solid, soft-gel and liquid<br />
pharmaceuticals. According to company statements,<br />
not only will they be able to deliver<br />
products at the same or lower cost compared to<br />
India or China, they will also be able to serve the<br />
entire North American market from this location<br />
with existing safety certification in the US, Canada<br />
and Mexico. Notably, a tri-country strategy<br />
might also facilitate (as well as potentially complicate)<br />
future measures to consider direct<br />
prescription drug importation from Mexico and<br />
throughout North America, as well.<br />
But pharmaceutical manufacturing is only one<br />
part of the life sciences industry in Mexico.<br />
Pharmaceutical companies (largely members of<br />
AMIIF) have also supported the development of<br />
strong clinical research clusters in key metropolitan<br />
regions, including the DF (Mexico City),<br />
Cuernavaca (Morelos), Guadalajara (Jalisco), and<br />
Monterrey (Nuevo León). According to AMIIF,<br />
clinical trials undertaken by their members have<br />
involved more than 1,250 institutions in Mexico,<br />
more than 2,000 researchers, and over 51,000<br />
patients (in 2005).<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [6]
These numbers are, in fact, increasing. While FDA-tracked clinical trials clearly are still concentrated<br />
primarily in the United States, a recent study by Thomson CenterWatch notes that the Latin American<br />
clinical research market has “experienced significant growth over the past 10 years, especially during<br />
the last five.”<br />
Why such growth? According to their 2005 survey of more than 300<br />
investigative sites in Latin America, some key elements are cited:<br />
large treatment-naïve populations, centralized health care systems,<br />
strong physician-patient relationships, high patient retention rates,<br />
Western-trained investigators, and disease patterns that reflect both<br />
developed and developing-world markets. In addition, participants in<br />
this survey also noted that faster patient enrollment has typically led<br />
to a lower proportion of trials delayed longer than one month<br />
(compared to sites in the US and Europe).<br />
As seen in the graphs at right, Mexico, in fact, while still “emerging”<br />
as a global location for clinical studies, actually ranks slightly higher<br />
in current or recently-completed studies than either India or China.<br />
Mexico-based clinical researchers also have significant experience not<br />
just in Phase III and IV trials, but also Phase II and an increasing number<br />
of Phase I clinical trials. And, most speak English and are geographically<br />
closer to California companies.<br />
Many studies are already also being conducted simultaneously in a<br />
binational (or multinational) context: a Phase III Merck study of HIV<br />
therapies that includes sites in <strong>San</strong> <strong>Diego</strong> and Mexico City (DF); a Phase<br />
II study for asthma treatments by Hoffmann-La Roche in <strong>San</strong> <strong>Diego</strong>,<br />
Monterrey, Guadalajara, and Mexico City; and a Phase III study by<br />
Pfizer/<strong>San</strong>ofi-Aventis for diabetes in <strong>San</strong> <strong>Diego</strong>, Mexico City and Monterrey<br />
are just three of many examples.<br />
Such binational protocols have the potential for not just speeding a life<br />
sciences discovery to market faster, but also could be used to leverage<br />
a multi-regional clinical trials network that increases the skill base of<br />
researchers as well as fosters a value-based mechanism for creating<br />
the human and physical infrastructure necessary for supporting<br />
Mexico’s emerging life sciences industry.<br />
Why Only Five Regions?<br />
While this initial briefing paper does not intend to<br />
be a comprehensive nor a definitive study of<br />
Mexico’s emerging life sciences industry, it is clear<br />
that the five states discussed in this document –<br />
Guanajuato, Jalisco, Morelos, Nuevo León, as well as<br />
Baja California – have some of the most-advanced<br />
life sciences facilities as well as some of the highest<br />
levels of human scientific capital in Mexico, as seen<br />
in this map showing the concentrations of SNI researchers<br />
by State. Other states, including Sonora,<br />
Tamaulipas, Colima, Yucatan and others, also have<br />
notable research capabilities in life sciences, but<br />
are not discussed here.<br />
<strong>San</strong> <strong>Diego</strong><br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [7]<br />
FDA/NIH-Tracked Clinical Trials<br />
(Active & Recent, May 2007)<br />
Brazil<br />
Mexico<br />
India<br />
China<br />
560<br />
501<br />
435<br />
423<br />
1,729<br />
0 500 1,000 1,500 2,000<br />
source: ClinicalTrials.gov<br />
FDA-Tracked Clinical Trials<br />
in Mexico - By Phase<br />
Phase IV<br />
Phase III<br />
Phase II<br />
Phase I<br />
1%<br />
11%<br />
23%<br />
64%<br />
0% 25% 50% 75%
Regions of Innovation in <strong>Life</strong> Sciences<br />
While over the coming months, more detailed briefings will be developed describing the life sciences<br />
infrastructure and activities within each State, a few highlights about these regions of innovation are<br />
presented below. Notably, as is the case with other technology centers throughout the world, these<br />
regions often are rooted around higher education centers – either public or private universities,<br />
Federal laboratories, and State technology institutes.<br />
As seen at right, all of them are substantially expanding<br />
their overall science base and SNI-registrations. In fact,<br />
increasing private sector interaction, new sources of funding,<br />
as well as plans by State and local governments to<br />
foster the growth of life sciences in these regions, could<br />
play a large role in catalyzing their development and capabilities<br />
over the coming decade. Other factors may also<br />
play an unexpected role – such as Mexico’s lack of<br />
prohibitions in stem cell research, as well as its more<br />
flexible immigration rules (which have the potential to<br />
foster international interactions that may be less-common<br />
or more difficult in the US).<br />
Guanajuato<br />
CINVESTAV researcher discussing<br />
genetic structure of maiz<br />
On arrival to the construction site of Mexico’s new National<br />
Genomics Laboratory for Biodiversity (LANGEBIO - Laboratorio<br />
Nacional de Genomica para la Biodiversidad), one is<br />
struck by the contrast between the simplicity of the surrounding<br />
strawberry fields and the vision of creating one of<br />
the world’s foremost laboratories dedicated to sequencing<br />
plant, animal, and microbial genomes of potential use for<br />
agricultural, medical and industrial applications. While the<br />
new 100,000 square foot facility is nearing completion adjacent<br />
to CINVESTAV – the Center for Research and Advanced<br />
Studies – LANGEBIO’s Director, Dr. Luis Herrera-Estrella (a<br />
member of the US National Academy of Sciences), has already led a team at the Laboratory to map out<br />
the more than 52,500 genes of maiz palomero – one of the oldest species of maiz, and known to many<br />
as pop corn.<br />
This accomplishment, coming only two years after the<br />
launching of LANGEBIO, is part of CINVESTAV’s 25 year<br />
history as a center for advanced biological and biotech<br />
research. Located in Irapuato, Guanajuato, this Federally-funded<br />
center (part of the National Polytechnic<br />
Institute’s network of research facilities) is actually one<br />
of Mexico’s centers of excellence in basic and applied<br />
research related to plant biology and agricultural biotech.<br />
Strong support from the State government and<br />
CONACYT has allowed CINVESTAV to develop well-respected<br />
Masters and Doctorate programs in plant<br />
biotechnology, with over 250 graduates from these<br />
programs to-date. In addition, CINVESTAV is home to<br />
800 SNI-Registered Researchers<br />
700<br />
(2005 & 2007) 692<br />
299 284<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [8]<br />
600<br />
500<br />
400<br />
300<br />
200<br />
100<br />
0<br />
410<br />
Baja<br />
California<br />
410<br />
446<br />
575<br />
741<br />
281<br />
451<br />
Guanajuato Jalisco Morelos Nuevo<br />
León<br />
2005 2007<br />
Some <strong>Biotech</strong> Projects in Guanajuato:<br />
Research into the production of natural<br />
insecticides using modified hairy-rooted<br />
plants<br />
Biocontrols of agricultural diseases using<br />
spores<br />
Development of a biological process that<br />
produces nanoparticulates of silver<br />
Altering plants to act as bioreactors to<br />
produce vaccines and other products
CINVESTAV research labs host life<br />
sciences visitors from US & Mexico<br />
over 30 researchers specializing in biochemistry,<br />
biotechnology, microbiology and plant biology.<br />
While CINVESTAV and LANGEBIO are perhaps the<br />
best known of the State’s 35 research centers,<br />
just a short drive away is the Instituto Tecnológico<br />
de Celaya (TECELAYA) – one of 218<br />
centers that make up Mexico’s National System of<br />
Technological Higher Education. TECELAYA offers<br />
a doctorate program in chemical<br />
engineering; as well as Masters and undergraduate<br />
degrees in chemical, mechanical, industrial<br />
and biochemical engineering. This last program –<br />
Biochemical Engineering – has a staff of more<br />
than 30 professors, a current Master’s program<br />
enrollment of nearly 40 students, and more than<br />
500 enrolled in the bachelor’s program.<br />
With an orientation toward bioengineering and<br />
molecular biotechnology, TECELAYA’s researchers<br />
also have developed an orientation toward<br />
commercial applications of their activities – particularly<br />
in the food and agricultural industry. In<br />
fact, while few patents have sprung from TECE-<br />
LAYA (a situation not uncommon in Mexico),<br />
several of their innovations have already been<br />
licensed by national and international companies<br />
– including a process using modified enzymes and<br />
bioreactors to allow higher extraction of natural<br />
pigment from marigolds - a process subsequently<br />
licenced to India-based AVT Natural Products and<br />
Chrysantis of Chicago.<br />
Additional life sciences-related institutions are<br />
also part of the Guanajuato cluster – among them<br />
the University of Guanajuato’s Research Institute<br />
in Experimental Biology; and INIFAP (Instituto<br />
Nacional de Investigaciones Forestales y Agropecuarias),<br />
a National research institution with a<br />
local center housing 60 researchers focused on<br />
forestry, agriculture, and animal sciences. With<br />
the State government undertaking vigorous efforts<br />
to develop additional industrial and<br />
technology parks, as well as educational and<br />
transportation infrastructure, Guanajuato appears<br />
to be positioning itself as a future leader in<br />
agricultural- and nutraceutical-related biotechnology.<br />
Jalisco<br />
What do wastewater from tequila production and<br />
antibiotics from frog skin have to do with life<br />
sciences? Both are the focus of current biotechnology<br />
research underway just West of<br />
Guanajuato – in the neighboring State of Jalisco.<br />
Better known in the US by its capital, Guadalajara,<br />
the State is one of Mexico’s largest with a<br />
population of nearly 7 million. It also is one of<br />
Mexico’s leading<br />
locations for clinical<br />
research,<br />
- 500 1,000 1,500 2,000<br />
health care, and Distrito Federal<br />
technology manu-<br />
Morelos<br />
facturing<br />
Estado de Mexico<br />
(including elec-<br />
Jalisco<br />
tronics,<br />
Nuevo León<br />
pharmaceuticals,<br />
Baja CA Sur<br />
and software).<br />
Veracruz<br />
As seen in the<br />
graph at right,<br />
Jalisco actually<br />
ranks fourth in<br />
the number of<br />
SNI-registered researchers<br />
that<br />
Guanajuato<br />
Yucatan<br />
Queretaro<br />
Michoacan<br />
Puebla<br />
Coahuila<br />
Baja CA<br />
are focused on life sciences (after the DF, Morelos,<br />
and Estado de México). It is also home to<br />
well-respected educational institutions and research<br />
centers in health, genetics, food,<br />
environmental and animal sciences – the largest<br />
being the Universidad de Guadalajara (UdeG).<br />
UdeG’s CUCBA (Centro Universitario de Ciencias<br />
Biológicas y Agropecuarias) alone has more than<br />
50 life sciences-related researchers registered<br />
with the SNI, approximately 300 professors, and<br />
nearly 3,000 students enrolled in undergraduate,<br />
graduate and doctoral programs – including neurobiology,<br />
molecular and cellular biology, seed<br />
and forest science, genetic reproduction, plant<br />
and animal biotechnology, and food science. This<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [9]<br />
<strong>Life</strong> Sciences Researchers<br />
Registered in SNI - By State<br />
(Agricultural & Veterinary<br />
Sciences, <strong>Life</strong> Sciences,<br />
Medicine & Human<br />
Pathology, Chemistry - 2005)
large cluster of students involved with biology has made UdeG the<br />
natural state-level organizer for Jalisco’s annual Olimpíadas de<br />
Biología – the Biology Olympics.<br />
While much smaller in size, the CONACYT-sponsored CIATEJ<br />
(Centro de Investigación y Asistencia en Tecnología y Diseño del<br />
Estado de Jalisco) and its over 80 researchers are also part of<br />
Jalisco’s life sciences research infrastructure – undertaking a variety<br />
of projects for agro-industrial and pharmaceutical companies,<br />
while also acting as a training ground and educational center for<br />
post-graduate students in biotechnology, food sciences, and environmental<br />
technology. Beyond education and projects, CIATEJ<br />
researchers also generate scientific publications and patents (19<br />
publications and 5 patent applications in 2005 alone).<br />
Guadalajara is also the home to another valuable resource: the<br />
Biocluster del Occidente – a non-profit group formed in 2005 to<br />
enhance the competitiveness of existing pharmaceutical and biomedical<br />
companies, as well as promote the development of new<br />
biomedical and biotech firms. Headed by Dr. Gregorio Cuevas – a<br />
scientist and entrepreneur with a doctorate in Applied Biochemistry from MIT – the Biocluster has<br />
brought together five universities (including the UdeG, ITESO, and the Universidad Autónoma de<br />
Guadalajara), as well as CIATEJ, and some of Jalisco’s major veterinary and pharmaceutical companies.<br />
The goal: to spur the growth of the life sciences industry in Jalisco and surrounding states, and<br />
to help protect and commercialize ideas developed by regional researchers.<br />
No discussion about life sciences in Jalisco can go without<br />
mentioning another research asset: the Hospital<br />
Civil de Guadalajara. The Hospital Civil is a teaching<br />
hospital affiliated with the UdeG, providing on a daily<br />
basis over 2,400 consultations, nearly 500 emergency<br />
room examinations, over 15,900 laboratory tests, and<br />
real-world learning experiences for 1,300 medical students.<br />
The Hospital Civil has the second-largest<br />
installed bed capacity in Latin America over its 12 floors,<br />
drawing patients from not just Jalisco, but from surrounding<br />
states as well.<br />
With a strong research focus, the Hospital has the only<br />
tissue bank in western Mexico. The Hospital currently<br />
has 20 researchers involved with 15 separate lines of study (including stem cells), and in 2006, 43<br />
clinical trials were initiated (all were Phase II or Phase III trials with multinational sponsorship).<br />
Despite such achievements, Hospital Civil is only just beginning to consider clinical trials a strategic<br />
part of its activities.<br />
Morelos<br />
Hospital Civil de Guadalajara<br />
(photo courtesy of Hospital )<br />
Somewhat overshadowed by the concentration of life sciences resources in adjacent Mexico City<br />
(Distrito Federal), Morelos stands apart as the state with the second-largest number of SNI-registered<br />
life sciences researchers (more than 300) and the second-largest number of members in Mexico’s<br />
Sociedad Mexicana de Bioquímica (Biochemistry Society - 58).<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [10]<br />
Frog-Based Antibiotics?<br />
Dr. Alfonso Islas and a small<br />
team from UdeG love frogs –<br />
or, at least the antibiotic<br />
properties in certain proteins<br />
that they’ve isolated<br />
and have been researching<br />
from the skin of the American<br />
Bullfrog.<br />
Working with both CONACYT<br />
and Laboratorios Veterinarios<br />
(LAVET), UdeG and Dr.<br />
Islas hope to turn this natural<br />
antibiotic into potential<br />
animal and human application<br />
following additional<br />
research…
This concentrated critical mass of human capital – largely in the city of Cuernavaca, Morelos – is made<br />
up of a large number of research centers – fifteen in all – focused on biology, biotechnology, genomics,<br />
and health. While the Universidad Nacional Autónoma de México (UNAM) dominates Morelos’ life<br />
sciences cluster, several other research centers are of note, including the Instituto Nacional de Salud<br />
Pública (National Institute of Public Health, one of Mexico’s leading health research centers, with<br />
specializations in diabetes, HIV, tuberculosis, and cancer, among others) and the Centro de Investigación<br />
en Biotecnología (Center for <strong>Biotech</strong>nology Research – CEIB) at the Universidad Autónoma del<br />
Estado de Morelos, focused on biological controls, natural products, and environmental remediation.<br />
However, it is UNAM’s Morelos campus that is the focal point for two major research centers. The<br />
Instituto de Biotecnología (<strong>Biotech</strong>nology Institute - IBt) is the largest, with approximately 100<br />
researchers, nearly 250 students (graduate and post-graduate) and technicians, and over 80,000 square<br />
feet of laboratory space. Founded in 1982 by early biotechnology pioneer, Dr. Francisco Bolivar (of<br />
pBR322 fame), IBt has become one of Mexico’s biotech centers of excellence, specializing in plant<br />
molecular biology, biocatalysis, molecular medicine and microbiology.<br />
UNAM-Morelos is also home to the recently founded Centro<br />
de Ciencias Genómicas (Center for Genomic Sciences –<br />
CCG), a university research center co-founded by Dr. Rafael<br />
Palacios (a member of the US National Academy of Sciences),<br />
and the result of a larger effort to study nitrogen-fixing<br />
microorganisms. Notably, CCG’s research staff of 35 recently<br />
announced the complete gene sequence of<br />
Rhizobium etli – a bacterium that lives symbiotically with<br />
the common bean.<br />
While many involved with Morelos’ life sciences industry are<br />
some of the country’s leading scientists, to date relatively<br />
few examples exist of that knowledge resulting in patents or commercial products. Probiomed – one<br />
of Mexico’s few domestic pharmaceutical and biotechnology companies – is one of the exceptions,<br />
establishing a strong research collaboration with the IBt that has resulted in the first domesticallycreated<br />
recombinant DNA-based pharmaceutical products in Mexico. Several other research collaborations<br />
with companies like Schering/Paion, Silanes, and Allied Domecq, are also underway at IBt.<br />
Patents and Culture<br />
Comparisons of global technology regions usually conclude that the low number of patents issued annually<br />
in Mexico must indicate a lack of ability or inventiveness. While patent applications in Mexico are certainly<br />
below what should be expected, the situation appears to be more complex than many conclude.<br />
In fact, while world-class research is often underway in these<br />
regions at university centers, there is little “cultural” emphasis at<br />
the institutions for protecting ideas for possible future commercialization<br />
– rather, peer prestige through publishing often trumps the<br />
desire to protect innovative ideas, and legal rules for some researchers<br />
create barriers for turning ideas into commercial products.<br />
Proximity to the US also leads some Mexican inventors to file<br />
applications there, avoiding Mexico’s patent system entirely. While<br />
100<br />
patent statistics typically only show the country of the “first listed<br />
inventor”, a review of US patent data done for this briefing shows<br />
nearly an equal number of US patents have a Mexico-residing<br />
inventor listed on the application, compared to the number of<br />
patents granted each year in Mexico to Mexico-based inventors.<br />
With many of Mexico’s creative minds employed by multinational<br />
companies, there is also an increasing number of US corporate<br />
50<br />
0<br />
55 59 65<br />
patent applications that have a Mexican inventor listed on US corporate patents…<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [11]<br />
300<br />
250<br />
200<br />
150<br />
CCG Laboratory<br />
(photo courtesy of UNAM)<br />
Patents Granted to<br />
Mexico-Based Inventors<br />
148 116 112<br />
1995<br />
1996<br />
1997<br />
141<br />
86<br />
1998<br />
120 118<br />
118<br />
139<br />
121<br />
162<br />
131 132<br />
101 104 120 135 118 122 107 100<br />
1999<br />
2000<br />
2001<br />
Mex Patents Granted to Mex Inventor (1st Inventor)<br />
US Patents Granted that Include Mex Inventor (any)<br />
2002<br />
2003<br />
2004<br />
2005<br />
2006
Nuevo León<br />
They call it the “International City of Knowledge” – otherwise known as Monterrey, Nuevo León. This<br />
metropolitan area is the center of a major push by the State government (in collaboration with Federal<br />
and local officials, as well as key educational institutions) to grow beyond the traditional model of<br />
“manufactura” (manufacturing production) to what they call “mentefactura” (“mind”-production).<br />
To do this, the State is focusing its economic development and educational programs toward high-tech<br />
industries -- among the priorities, biotechnology and medical services.<br />
Much of their effort has been focused on schools. According to State officials, more than 32,000<br />
children are studying under updated educational programs that stress science and innovation. In<br />
addition, more than US$50 million in State and Federal funds has been invested in a variety of<br />
technology projects, including the construction of a new Parque de Investigación é Innovación<br />
Tecnológica (PIIT - Research and Innovation Technology Park). The PIIT – built just minutes from<br />
Monterrey’s airport – will have six research centers and from various universities (including the<br />
Universidad Autónoma de Nuevo León [UANL], CINVESTAV, and ITESM-Monterrey Tec), as well as<br />
incubator space for IT firms, and a global business center affiliated with the University of Texas.<br />
While some evidence exists that biotech spin-offs are starting to form (particularly from long-time<br />
industry promoters, such as Dr. Hugo Barrera – a professor at UANL), universities continue to be the<br />
focal point for life sciences activity. Largest in Nuevo León is the UANL – considered the strongest<br />
research university in Northeast Mexico, with over 145 life sciences-related researchers alone in<br />
Mexico’s SNI registry (48 of which are in the School of Biological Sciences). While the UANL School of<br />
Medicine offers a wide range of Doctoral and Masters degrees<br />
in medical and biomedical research, its Biological Sciences<br />
program has 130 professors focused on biology, food sciences,<br />
and biotechnology. UANL also has a Centro de Incubación de<br />
Esmpresas y Transferencia de Tecnología (Center for Business<br />
Incubation and Technology Transfer - CIETT) to support the<br />
future growth of those emerging spin-offs.<br />
Over at Monterrey Tec (ITESM), another biotech investment<br />
has also taken shape: a new, US$35 million <strong>Biotech</strong>nology<br />
Center that aims to integrate the school’s chemical engineering,<br />
food, biology, and medical talent into new innovations<br />
and new businesses. The Center is a four story facility with<br />
food safety testing labs, bioreactors, and research lab space<br />
surrounded by undergraduate and post-graduate science class-<br />
rooms. With a strong interest in connecting their capabilities to the international marketplace, the<br />
Director of the Centro de Biotecnología made a point during a recent visit – the informational brochure<br />
used to promote the Center was printed in only one language: English.<br />
UANL’s Hospital Universitario<br />
Monterrey’s life sciences industry continues to grow, supported<br />
by its strong clinical trials capabilities. Many of these,<br />
in fact, occur at the UANL-affiliated teaching hospital<br />
(Hospital Universitario) and ITESM’s Hospital <strong>San</strong> José (the two<br />
largest centers for clinical research in Nuevo León). With the<br />
new Council of Specialized Medical Services (formed to promote<br />
Monterrey as a “health tourism” destination), additional<br />
growth in medical services and clinical trials is likely, both at<br />
university sites, and at a small number of start-ups (such as<br />
Monterrey-based DeBBiOM) which will serve US firms seeking<br />
clinical research options, as well as domestic firms facing<br />
Mexico’s new generics bioequivalency requirements.<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [12]<br />
Dr. Simon Goldbard visits with<br />
Dr. Mario Alvarez, Director of<br />
ITESM’s <strong>Biotech</strong>nology Center
The <strong>Life</strong> Sciences Potential of Baja California<br />
Just south of <strong>San</strong> <strong>Diego</strong>, one can find not only the largest concentration of biomedical device companies in<br />
Mexico – but a small but growing number of biotech researchers and entrepreneurs, as well. Highlighted<br />
in <strong>Borderless</strong> Innovation, the Baja California biotechnology cluster is located primarily in Ensenada with its<br />
concentration of educational and research institutions, such as the Centro de Investigación Científica y de<br />
Educación Superior de Ensenada (CICESE), and the Universidad Autónoma de Baja California (UABC). In<br />
fact, Ensenada’s centers are themselves a reflection of historic crossborder leadership, as it was a<br />
contingent of representatives from UNAM, CONACYT, and UABC that visited the Scripps Institute of<br />
Oceanography in La Jolla as part of a feasibility study that led to the creation of what is now known as<br />
CICESE in 1973.<br />
Currently, CICESE’s Doctoral and Master’s degree programs in marine biology and biotechnology play a<br />
large role in Baja California’s future biotech potential (particularly in marine biotechnology), as does<br />
UABC’s Doctoral program in agricultural biotechnology and its Master’s programs in desert ecology,<br />
veterinary sciences, and health. The Instituto Tecnológico de Tijuana (Tijuana Technology Institute) also<br />
has Doctoral and Masters programs in chemistry, adding further life sciences potential to a region whose<br />
workforce is highly educated in global manufacturing and production.<br />
While Baja California does not have the largest number of SNI-registered life sciences researchers, it does<br />
have something few other regions in Mexico can claim – interaction with and proximity to one of the largest<br />
concentrations of biotech research and capital in the United States: <strong>San</strong> <strong>Diego</strong>.<br />
<strong>San</strong> <strong>Diego</strong>: A Portal for <strong>Borderless</strong> <strong>Biotech</strong>?<br />
This document is yet another part of a continuing effort to describe Mexico’s evolution in technology<br />
and science. Clearly, certain intriguing crossborder opportunities appear to exist in the case of life<br />
sciences – whether in ag-biotech, biocontrols, genomics research, pharmaceutical manufacturing,<br />
medical devices, or clinical trials. While all of Mexico cannot expect to immediately become a<br />
world-leader in all areas of this sector, its history already shows examples of regional genius and<br />
connections with California’s biotech and pharmaceutical industries. The question remains: can this<br />
history be expanded upon - and will it include <strong>San</strong> <strong>Diego</strong>?<br />
Given that <strong>San</strong> <strong>Diego</strong> has the largest concentration of US-based biotechnology firms along the<br />
US-Mexico border and one of the largest in the United States, there is a strong case and a unique<br />
opportunity to work with the dynamic regions that make up Mexico’s emerging life sciences industry.<br />
Direct flights from both <strong>San</strong> <strong>Diego</strong>’s or Tijuana’s airports to these regions provides access that few<br />
other locations in the United States can take advantage of. The broad use of English by many of<br />
Mexico’s technology leaders eliminates yet another barrier to increased interaction, scientific collaboration,<br />
and possibly investment. Such an opportunity, first discussed in <strong>Borderless</strong> Innovation, can<br />
help act as a catalyst for both increasing multi-regional competitiveness in life science companies, as<br />
well as accelerate Mexico’s growth in this sector.<br />
Just as the strength of a helix is based on the connections between<br />
its components, so too the potential for <strong>San</strong> <strong>Diego</strong> to become both<br />
a portal and a partner for <strong>Mexico's</strong> emerging life sciences regions<br />
creates opportunities for each side of the crossborder region.<br />
Joining together the talent and capabilities of <strong>San</strong> <strong>Diego</strong>, Guanajuato,<br />
Jalisco, Morelos, Nuevo León, and Baja California in the<br />
development of a life sciences partnership may create a unique,<br />
international model that goes beyond borders. Ultimately, such a<br />
partnership might also extend to many other regions – in the US,<br />
Mexico, Canada, Europe and Asia – supporting new job growth, new<br />
discoveries, and a world of borderless biotech.<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [13]
Appendix - Websites for Additional Information<br />
Asociación Farmacéutica Mexicana www.afmac.org.mx<br />
Asociación Mexicana de Industrias de Investigación<br />
Farmacéutica<br />
www.amiif.org.mx<br />
Banco Nacional de Patentes (Mexico, searchable) www.impi.gob.mx/banapanet<br />
Cámara Nacional de la Industria Farmacéutica www.canifarma.org.mx<br />
Centro de Biotecnología - ITESM www.mty.itesm.mx/dia/ing_agricola/cbt.htm<br />
Centro de Investigación y Asistencia en Tecnología del<br />
Estado de Jalisco<br />
www.ciatej.net.mx<br />
Centro Universitario de Ciencias Biológicas y<br />
Agropecuarias - UDG<br />
www.cucba.udg.mx<br />
CICESE – Marine <strong>Biotech</strong>nology Department biotecnologia.cicese.mx<br />
CINVESTAV – Irapuato Campus www.ira.cinvestav.mx<br />
CONACYT - Consejo Nacional de Ciencia y Tecnología www.conacyt.mx<br />
Council on Competitiveness – Mexico Projects www.compete.org/gi/us_mexico.asp<br />
INMEGEN – Instituto Nacional de Medicina Genómica www.inmegen.gob.mx<br />
Instituto de Biotecnología - UANL www.fcb.uanl.mx/Mis_Webs/InicioIB.htm<br />
Instituto de Biotecnología - UNAM www.ibt.unam.mx<br />
Instituto de Investigaciones Oceanológicas - UABC iio.ens.uabc.mx<br />
Premios a la Innovación en Salud y Alimentación www.premiosinnovamex.com.mx<br />
Secretaría de Salud www.salud.gob.mx<br />
<strong>San</strong> <strong>Diego</strong> <strong>Dialogue</strong> www.sandiegodialogue.org<br />
Sociedad Mexicana de <strong>Biotech</strong>nología y Bioingeniería www.smbb.com.mx<br />
This Forum Fronterizo briefing paper was developed by <strong>San</strong> <strong>Diego</strong>-based Crossborder Group Inc.<br />
(www.CrossborderBusiness.com) under contract with UCSD Extension and <strong>San</strong> <strong>Diego</strong> <strong>Dialogue</strong>, with<br />
the generous support of Merck. The opinions expressed in this briefing paper do not necessarily reflect<br />
those of <strong>San</strong> <strong>Diego</strong> <strong>Dialogue</strong>; the University of California, <strong>San</strong> <strong>Diego</strong>; Merck; or Merck Sharpe & Dohme.<br />
If you would like more information about Mexico’s emerging life sciences industry, please contact UCSD<br />
Extension-<strong>San</strong> <strong>Diego</strong> <strong>Dialogue</strong> at (858) 534-8638, or visit our website at www.<strong>San</strong><strong>Diego</strong><strong>Dialogue</strong>.org; for<br />
additional information about UCSD Extension’s Global Connect program, please visit our website at<br />
globalconnect.ucsd.edu.<br />
<strong>Borderless</strong> <strong>Biotech</strong> & <strong>Mexico's</strong> <strong>Emerging</strong> <strong>Life</strong> Sciences Industry -- [14]